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Abstract
Background: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one
of the most important dose-limiting toxicity of this drug. It occurs in around 60–80% of the patients, and 15% of
them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear. SCN9A is a
gene codifying for a subtype sodium channel (type IX, subunit α) and mutations in this gene are involved in
neuropathic perception. In this study we investigated whether SCN9A genetic variants were associated with risk of
neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin.
Methods: Blood samples from 94 patients diagnosed of digestive cancer that had received oxaliplatin in adjuvant
or metastatic setting were obtained from three hospitals in Madrid. These patients were classified into two groups:
“cases” developed oxaliplatin-induced grade 3–4 neuropathy (n = 48), and “controls” (n = 46) had no neuropathy
or grade 1. The neuropathy was evaluated by an expert neurologist and included a clinical examination and
classification according to validated neurological scales: National Cancer Institute Common Toxicity Criteria (NCI-CTC),
Oxaliplatin-Specific Neurotoxicity Scale (OSNS) and Total Neuropathy score (TNS). Genotyping was performed for 3
SCN9A missense polymorphisms: rs6746030 (R1150W), rs74401238 (R1110Q) and rs41268673 (P610T), and
associations between genotypes and neuropathy were evaluated.
Results: We found that SCN9A rs6746030 was associated with protection for severe neuropathy (OR = 0.39, 95% CI = 0.
16–0.96; p = 0.041). Multivariate analysis adjusting for diabetes provided similar results (p = 0.036). No significant
differences in neuropathy risk were detected for rs74401238 and rs41268673.
Conclusion: SCN9A rs6746030 was associated with protection for severe oxaliplatin-induced peripheral neuropathy.
The validation of this exploratory study is ongoing in an independent series.
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Background
Oxaliplatin is a subtype of platinum drugs with signifi-
cant activity against advanced or metastatic digestive tu-
mors, mainly colorectal cancer (CRC) [1]. Peripheral
neuropathy (PN) is a dose-limiting toxicity of oxaliplatin
and classically induces two recognized forms of PN:
acute and chronic [2].
Whereas acute PN is not dose-dependent, cumulative
doses of oxaliplatin are related to occurrence of chronic
peripheral neuropathy [3]. The acute neurotoxicity oc-
curs in a high rate of oxaliplatin-treated patients, and it
usually occurs during or within hours of infusion, and it
is transient. The majority of the symptoms (including
paresthesias and/or dysesthesias in the distal extremities
and the perioral region) are typically induced by cold ex-
position and clinical features include distal sensory neur-
opathy. Chronic neuropathy is a dose-limiting toxicity
defined as a cumulative sensory toxicity. The median
* Correspondence: mariasereno75@gmail.com
1Medical Oncology Department, Infanta Sofía University Hospital, SS de los
Reyes, Madrid, Spain
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sereno et al. BMC Cancer  (2017) 17:63 
DOI 10.1186/s12885-016-3031-5
dose for severe neuropathy is 780–850 mg/m2, and it is
seen in 10–15% of patients [1]. It is a pure sensory,
mostly axonal neuropathy with a stocking-and-glove dis-
tribution. Symptoms typically are presented between cy-
cles and increase in intensity with cumulative dose.
Several factors have been described to increase the risk
of severe PN: previous neuropathies, Guillain-Barré syn-
drome, diabetes mellitus, anemia, hypoalbuminemia,
hypomagnesemia and alcohol consumption, as well as
have had a recent surgery [4]. However, a large part of
the severe neuropathy cases remain unexplained and
more studies are needed to discover the underlying fac-
tors and to identify patients with a high risk to develop
severe PN.
Several markers have been described as potential pre-
dictors for acute and chronic oxaliplatin-induced neur-
opathy (OXLIN) [5–7]. However, none of these have
been validated in prospective studies.
The voltage-gated sodium channels are presented in
dorsal root ganglion (DRG) and sympathetic ganglion
cells, as well as in their small-diameter peripheral axons.
They are involved in the initiation and propagation of
potentials. They act as gatekeepers of pain at peripheral
nociceptors. Nine sodium channel subunits are de-
scribed (Nav1.1-Nav1.9) [8]. SCN9A gene encodes
Nav1.7 isoform. Mutations in SCN9A have been associ-
ated with different “channelopathies” with electrical
hyperactivity of sensory neurons in dorsal root and a
low reactivity of sympathetic ganglia neurons [9]. There
are three human pain disorders related to these type of
genetic disorders: a bi-allelic loss of function mutations
(channelopathy-associated Insensitivity to Pain, CIP),
and the opposite situation, an activating mutations with
severe episodic pain in Paroxysmal Extreme Pain Dis-
order (PEPD) and Primary Erythromelalgia (PE) [10].
Moreover; a polymorphism in SCN9A gene (rs6746030)
was associated with pain intensity perception in patients
with different painful diseases, making DRG neurons
more excitable as well as susceptible to aberrant pain
perception [11]. Taking into account these evidences, we
designed a study to explore the role of SCN9A common
genetic variants in OXLIN development in patients diag-
nosed of digestive tumors that had undergone treatment
with oxaliplatin.
Methods
Patient Selection and OXLIN evaluation
From 2012 to 2014, one hundred adults with a histologi-
cally confirmed diagnosis of digestive tumor (colon, rec-
tum, gastric, pancreatic and biliary duct cancers in
different stages) were recruited in three Spanish Hospi-
tals (Infanta Sof ía University Hospital, La Paz University
Hospital and Infanta Leonor University Hospital). All
patients had received an oxaliplatin based regimen (at
least 780–800 mg/m2 of oxaliplatin dose) during the last
6 months previous to inclusion. Additional details about
the type of tumor and treatment regimens are summa-
rized in Table 1. All cancer patients were over 18 years;
life expectancy of ≥3 months; Eastern Cooperative
Oncology Group (ECOG) performance status of ≤2;
adequate bone marrow, renal and hepatic function; and
no previous history of neuropathy. The study was ap-
proved by La Paz University Hospital Ethic committee
in December 2011 and all patients signed and gave writ-
ten informed consent.
Inclusion criteria for cases were to have a digestive
tumor; receiving oxaliplatin based regimen; cumulative
doses 780–850 mg/m2, and the development of a severe
neuropathy (NCI-CTC grade 3–4). Inclusion criteria for
controls were also to have a digestive tumor; receiving
oxaliplatin based regimen; cumulative dosis 780–850 mg/
m2 and to have no neuropathy or mild neuropathy (NCI-
CTC grade 0–1). Exclusion criteria for cases and controls
was suffering a previous peripheral neuropathy.
The selected 100 patients were divided into two ex-
treme groups: patients with a severe neuropathy and pa-
tients without neuropathy after receiving similar
regimens and doses of oxaliplatin. This strategy was
established to optimize the search of genetic differences
between these opposite groups. According to this, fifty
patients were defined as “cases”, those patients who
developed an extreme and severe sensory neuropathy
(defined as NCI-CTC grade 3); and fifty patients were
defined as “controls”, those patients with no neuropathy
or grade 1 neuropathy according to clinical scales (NCI-
CTC grade 0–1) after receiving similar doses of oxalipla-
tin (Table 1).
To perform the clinical evaluation and the neuropathy
grading in a homogeneous manner across the different
collaborative centers, all patients included in the study
underwent a comprehensive neurological examination by
the same neurologist as well as neurophysiological studies,
performing sural and peroneal conduction studies accord-
ing to standardized protocols with a Nihon-Kohden elec-
tromyography and comparing them to normalized data
from the EMG laboratory. The final classification of
patients in cases and controls was performed according to
the Total Neuropathy Score (TNS) and subscales scores
(clinical and reduced, TNSc and TNSr). Cases were
considered all those patients with a TNS > or = 15 and
controls those patients with TNS value < or = 6 (Table 1).
From the 100 patients recruited, 94 gave blood samples
and completed a neurological evaluation and were in-
cluded in the analysis.
DNA extraction and SNP genotyping
FlexiGene DNA Kit (Qiagen) was used to isolate DNA
from the blood samples of the patients. Final DNA
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analysis was made in 94 patients, 46 cases and 48 con-
trols. Three SNPs in SCN9A (rs41268673, rs6746030 and
rs74401238) were selected for genotyping using the
KASPar SNP Genotyping System (LGC Genomics, UK)
with 15 ng of genomic DNA. All assays included DNA
samples with known genotypes and negative controls.
The Sequence Detection System ABI PRISM® 7900HT
(Applied Biosystems) was employed for fluorescence
detection and allele assignment.
Statistical analysis
Clinical variables among cases and controls were com-
pared using Student t-test/Mann-Whitney U test (age
and cumulative dose of oxaliplatin) or Chi2 test (gender,
presence of diabetes mellitus, tumor type, chemotherapy
regimen and tumor stage). Association between OXLIN
(cases vs controls) and SCN9A polymorphisms was
assessed using binary logistic regression analysis. In the
multivariate binary logistic regression analysis, diabetes
mellitus was included as covariate. We considered an
additive genetic model for the SNPs evaluated, and when
P value was <0.1, other genetic models were explored.
Mann-Whitney U test was used to compare TNS grade
between the different SCN9A genotypes. The SPSS
software package v.19 was used for all statistical ana-
lyses. P values less than 0.05 were considered statisti-
cally significant.
Results
The overall demographic and clinical characteristics of
the series are represented in Table 1. All patients in-
cluded received oxaliplatin treatment during at least
6 months (doses 780–850 mg/m2), according to the
following protocols: eight courses of XELOX regimen:
(Capecitabine) xeloda and oxaliplatin; 12 courses of
FOLFOX regimen: 5-fluorouracil, folinic acid (leucov-
orin) and oxaliplatin; eight courses of TOMOX: ralti-
trexed and oxaliplatin; six courses of EOX: epirubicin,
oxaliplatin and xeloda; or 12 courses of FOLFIRINOX:
5-fluorouacil, folinic acid, irinotecan and oxaliplatin.
The severity of the acute OXLIN was evaluated before
every cycle and chronic or persistent toxicity was evalu-
ated up to 3 months after last chemotherapy cycle.
According to this, patients were classified in cases and
controls according to TNS scale. We established that all
those patients with a moderate or severe OXLIN (TNS
score ≥ 15) were “cases” (46 patients) and those with
inexistent or mild OXLIN (TNS ≤6) were “controls” (48
patients). The clinical characteristics of these patients
were similar, except for diabetes mellitus, which was
over-represented in the cases (Table 1).
Among the 94 patients studied, 41 (44%) patients pre-
sented “coasting effect” (that is, a worsening of neur-
opathy after finishing chemotherapy), 18 (20%) had dose
reductions (around 25–30%) and 10 (12%) patients sus-
pended chemotherapy because of the neuropathy. We
Table 1 Demographic and clinical characteristics of the series
Variables Cases (TNS≥ 15;
n = 46)
N (%)
Controls (TNS≤ 6;
n = 48)
N (%)
P value*
Sex ns
Female 14 (30%) 16 (33%)
Male 32 (70%) 32 (67%)
Age ns
Median (min-max) 65 (41–83) 66 (36–82)
Diabetes 0.0055
Yes 11 (24%) 2 (4%)
No 35 (76%) 46 (96%)
Hypothyroidism ns
Yes 0 (0%) 0 (0%)
No 46 (100%) 48 (100%)
Tumor location ns
Colon 23 (50%) 30 (63%)
Rectum 9 (20%) 7 (15%)
Biliary duct 2 (4%) 2 (4%)
Pancreas 3 (6%) 4 (8%)
Stomach 9 (20%) 5 (10%)
Type of chemotherapy ns
XELOX 35 (76%) 29 (61%)
-Adjuvant 25 20
-Palliative 10 9
FOLFOX 6 (13%) 11 (23%)
-Adjuvant 3 8
-Palliative 3 3
TOMOX 0 (0%) 2 (4%)
-Adjuvant 0 0
-Palliative 0 2
FOLFIRINOX 1 (2%) 2 (4%)
-Palliative 1 2
EOX 4 (9%) 4 (8%)
-Perioperative 4 4
-Palliative 0 0
Stage AJCC ns
I-II 18 (39%) 16 (33%)
III-IV 28 (61%) 32 (67%)
Cumulative dose of
oxaliplatin (mg)
ns
Median (min-max) 1616 (880–2045) 1624 (900–2050)
*P values >0.05 are indicated as non significant (ns)
TNS: Total Neuropathy Score > 15
TNS: Total Neuropathy Score < 6
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found that all patients with severe acute OXLIN (TNS
≥15) also developed a chronic/cumulative disease.
Association between OXLIN and SCN9A genotypes
With regards to genotyping, 3 SCN9A missense polymor-
phisms with a minimum allele frequency >2% in the
European population (rs6746030 (p.R1150W), rs74401238
(p.R1110Q) and rs41268673 (p.P610T), were genotyped in
the 94 patients. We identified 64 C/C, 29 C/T and 1 T/T
patients for rs6746030 (p.R1150W). For rs41268673
(p.P610T) three individuals were heterozygous and the
rest were homozygous wild type, and for rs74401238
(p.R1110Q) five were heterozygous and 89 were homozy-
gous wild type.
We found that rs6746030 variant carriers had signifi-
cantly lower neuropathy (OR = 0.39; 95% CI = 0.16–0.96;
p = 0.041; dominant model) than wild-type patients.
These findings suggest that SCN9A rs6746030 (p.R1150W)
variant allele protects against the development of
moderate-severe OXLIN (Table 2). Among the different
clinical factors analyzed (gender, age, diabetes mellitus, type
of tumor, chemotherapy regimen) only diabetes mellitus
was significantly associated with moderate-severe OXLIN
(OR = 7.23; 95% CI = 1.51–34.73; p = 0.014) (Table 3).
Multivariate analysis adjusting for diabetes mellitus did not
substantially changed the association of SCN9A rs6746030
polymorphism with OXLIN (OR= 0.36; 95% CI = 0.14–
0.94; p = 0.036) (Table 3).
When TNS grade was compared with rs6746030 geno-
type, in multivariable analysis adjusting by diabetes mel-
litus, the variant carriers had protection against OXLIN
(OR = 0.89; 95% CI = 0.81–0.99; P = 0.044).
The other two SCN9A SNPs studied were not associ-
ated with OXLIN development in the population in-
cluded in the study (Table 2). However, the low number
of carriers for SCN9A rs74401238 (p.R1110Q) and
rs41268673 (p.P610T) indicates a low statistical power
in the analysis.
Discussion
Oxaliplatin peripheral neuropathy affects a large number
of patients and can lead to treatment suspension. Most
patients recover from the neuropathy in a variable
period of time, but long-term nerve damage can also
occur, compromising the quality of life of these patients
[12, 13]. Several studies have tried to explain OXLIN
mechanism, but, so far, the molecular bases for it remain
unknown. In this study we proposed that alterations in
Na channel structure could increase susceptibility for
OXLIN development. Previous studies have shown that
oxaliplatin causes a functional channelopathy induced by
oxalate affecting channels located in cellular membrane
[14]. Several preclinical studies with animal models
suggested that oxaliplatin modulates the axonal voltage-
gated sodium channels inducing a slow sodium channel
kinetics, shifting the voltage dependence to more nega-
tive potentials [15]. However, it is not clear what are the
mechanisms that justify the development of an acute
“sodium channelopathy” in oxaliplatin-treated patients,
with inconsistent in vitro studies concerning the role of
transient and persistent Na + conductances [16]. In
addition to the “channelopathy hypothesis”, other studies
have described the “oxidative hypothesis”, supported by
primary cultures of astrocytes activated in vivo by oxali-
platin treatment. According to the hypothesis of channel
disorders induced by oxaliplatin, OXLIN happens when
oxaliplatin is accumulated in dorsal root ganglia (DRG)
cells. This event, as well as mitochondrial dysfunction
with alteration in redox metabolism, is able to induce
DRG cells apoptosis [17, 18].
Diabetes has been related to a higher risk to develop
neuropathy with different anticancer drugs. Kus T et al.
demonstrated in a retrospective analysis that paclitaxel-
based therapy in diabetic patients with breast cancer,
diabetes duration above 5 years could affect the inci-
dence and severity of PSN without known baseline neur-
opathy [19]. De la Morena et al. found similar findings
in patients with breast cancer treated with paclitaxel
every week. They demonstrated that preexisting diabetes
Table 2 SCN9A SNPs included in the study with genotype
frequencies among cases and controls
SNP Total nr. of
patients
Cases TNS≤ 6
(n = 48)
Controls TNS≥ 15
(n = 46)
P value*
rs6746030 0.041
C/C 64 23 (48%) 41 (89%)
C/T 29 24 (50%) 5 (11%)
T/T 1 1 (2%) 0 (0%)
rs41268673 0.589
C/C 91 46 (96%) 45 (98%)
C/A 3 2 (4%) 1 (2%)
A/A 0 0 (0%) 0 (0%)
rs74401238 0.683
G/G 89 45 (94%) 44 (98%)
G/A 5 3 (6%) 2 (2%)
A/A 0 0 (0%) 0 (0%)
*Univariate binary logistic regression analysis
Table 3 Association of rs6746030 with OXLIN under a dominant
genetic model
Variable OR 95% CI P value
rs6746030 univariate 0.39 0.16–0.96 0.041
rs6746030 multivariatea 0.36 0.14–0.94 0.036
Diabetes mellitus 7.23 1.51–34.73 0.014
aMultivariate binary logistic regression analysis adjusting for diabetes mellitus
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was associated with long-lasting significant neuropathy
[20]. As well as with Taxol, several authors have de-
scribed that diabetic patients are more vulnerable to de-
velop OXLIN. Uwahn AN et al. found that although the
presence of diabetes did not appear to affect the severity
of OXLIN, patients with diabetes could develop OXLIN
with lower doses of oxaliplatin (P < .05) [21].
However, no molecular studies have identified markers
able to predict OXLIN development. Argyriou A et al.
found polymorphisms in different voltage-gated sodium
channels with a potential role in predicting severe acute
and chronic OXLIN. They found that the experimental
model of the skeletal muscle sodium channel SCN4A
rs2302237 and the tetrodotoxin-resistant SCN10A
rs1263292 polymorphisms could be related to the
development of acute OXLIN [22, 23].
SCN9A encodes Nav1.7 isoform and it plays an im-
portant role in defining of threshold for excitation of
nociceptors and can control neurotransmitter release at
the terminals of these receptors. Homozygous loss of
function mutations in Nav1.7 has been related to a con-
genital inability to suffer pain and anosmia in men. In
addition, heterozygous gain of function mutations have
been described in different clinical pain syndromes of
inherited erythromelalgia (IEM: pain and erythema exac-
erbated by warming), paroxysmal extreme pain disorder
(PEPD: proximal pain and autonomic features in ocular/
mandibular and sacral regions), and small fiber neur-
opathy (SFN: degeneration of small diameter sensory
and autonomic axons presenting with a severe burning
pain) [24]. As we already have mentioned, different mu-
tations in SCN9A gene could cause chronic pain and
pain insensitivity syndromes [25]. For example, Peddar-
eddygari LR et al. demonstrated that homozygous
p.G2755T mutation in exon 15 of this gene is associated
with congenital insensitivity to pain (CIP) [26, 27]. Other
authors have related some mutations like p.L1612P with
a Cold Sensitive Paroxysmal Extreme Pain Disorder [28].
According to these data and the role of this gene in pain
and cold perception, we decided to analyzed SCN9A
missense SNPs (rs6746030 (p.R1150W), rs74401238
(p.R1110Q) and rs41268673 (p.P610T)) as a potential
cause of genetic susceptibility for a cold-induced neur-
opathy like OXLIN. We found that SCN9A rs6746030
variant allele protected against the development of
moderate-severe OXLIN in univariate and multivariate
analysis (p = 0.041 and p = 0.036, respectively).
A validation in a prospective series of patients receiv-
ing oxaliplatin is needed to confirm this association. We
could not obtain any conclusions about the other two
SNPs because of low frequency in European population.
In addition, we analyzed the correlation between
chronic and acute OXLIN. We observed that all patients
considered “cases”, with severe acute OXLIN, also had a
moderate-severe chronic/cumulative neuropathy. Argyriou
et al. also demonstrated this correlation in a cohort of pa-
tients with OXLIN. A possible explanation for this could
be the cellular stress affecting the sensory cells as a result
of the prolonged activation of SCNAs, inducing a decrease
of neuron metabolism and axoplasmic function in the
DRG cells [18]. Preclinical data with sural nerve cultures
exposed to oxaliplatin showed alterations in sodium chan-
nel kinetics and prolonged opening of sodium channels
resulting in an increase in sodium currents [29].
Conclusion
In conclusion, OXLIN is a multifactorial disease. Dia-
betes mellitus and previous neuropathy increase the risk
for developing OXLIN; however, so far, no genetic pre-
disposition markers have been defined. In this study, we
found that SCN9A rs6746030 (p.R1150W) variant allele
is associated with a protective effect against developing
moderate-severe OXLIN. Prospective evaluation of these
findings is needed to confirm the role of this SCN9A
polymorphism in OXLIN development.
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